Dr. Stover discusses research on UGN-102 in non–muscle-invasive bladder cancer

The EV-302 trial is the confirmatory trial for the FDA’s accelerated approval of pembrolizumab plus enfortumab vedotin for the first-line treatment of patients with locally advanced or metastatic urothelial carcinoma.

In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.

Patients with MIBC were randomly assigned to receive APL-1202 in combination tislelizumab or to tislelizumab alone.

“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.

BT8009 targets the tumor antigen Nectin-4, which has elevated expression levels in urothelial cancer.

The EU application for erdafitinib in urothelial carcinoma is supported by data from cohort 1 of the phase 3 THOR trial.